Inflammation and Infective Endocarditis
Launched by BARTS & THE LONDON NHS TRUST · Mar 5, 2025
Trial Information
Current as of May 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a serious heart condition called infective endocarditis (IE), which occurs when bacteria enter the bloodstream and attach to heart valves, causing damage. The researchers believe that the immune system may be overactive in these patients, potentially worsening the condition by attacking the heart itself. They want to find out if certain immune cells in the blood and valve tissue can help identify patients who have an autoimmune response related to IE. This information could lead to new treatments that help manage the disease more effectively.
To participate in the trial, individuals must have a confirmed diagnosis of infective endocarditis based on specific medical criteria. Unfortunately, those currently dealing with active cancer cannot join. Participants will undergo tests to analyze their immune cells, which may involve a blood sample and tissue taken during surgery. The study is not yet recruiting, but it aims to improve understanding and treatment options for people affected by this serious illness.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • A clinical diagnosis of infective endocarditis according to the Duke Criteria.
- Exclusion Criteria:
- • Active solid organ or haematological malignancy.
About Barts & The London Nhs Trust
Barts and The London NHS Trust is a leading healthcare organization in the United Kingdom, renowned for its commitment to delivering high-quality clinical care, research, and education. As a prominent sponsor of clinical trials, the Trust is dedicated to advancing medical knowledge and improving patient outcomes through innovative research initiatives. With a focus on patient safety and ethical standards, Barts and The London NHS Trust collaborates with multidisciplinary teams to explore cutting-edge therapies and interventions across various medical fields, ensuring that trial participants receive the highest level of care and support throughout their involvement.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Patients applied
Trial Officials
Federica Marelli-Berg, MD PhD
Study Director
Queen Mary University of London
Simon Woldman, MD
Study Director
Barts & The London NHS Trust
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported